Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview

Sharma, Meenakshi; Chadha, Renu; Dhingra, Neelima

doi:10.2174/1389557516666160621103817

Cited by 22 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plant extracts are a class of herbal medicines that remain somewhat controversial and are not yet recommended by the EAU or AUA for the treatment of BPH. Such treatments predominantly include extracts from Saw palmetto, Cucurbita pepo L., Prunus africana, Urtica dioica L, and Secale cereale L. (Sharma et al, 2017). Phytotherapies have not yet been accepted by the EAU and AUA because of methodological problems and heterogeneity in the clinical trials carried out thus far.…”

Section: Plant Extractsmentioning

confidence: 99%

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Yan

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is the most common benign disease of the prostate gland and is caused by benign hyperplasia of the smooth muscle cells and stromal cells in this important gland. BPH is also the most common disease underlying lower urinary tract symptoms (LUTS). The incidence of BPH increases with age and affects more than half of all men 50 years or older. BPH mainly exerts effects on urinary function and can seriously reduce a patient's quality of life. At present, treatment for BPH aims primarily to improve the quality of life and reduce the risk of BPH-related complications. Pharmacological therapy is recommended for moderate-to-severe cases of LUTS that are suggestive of BPH. A range of drugs is currently available to treat this condition, including a1adrenoceptor antagonists, 5a-reductase inhibitors (5-ARIs), phosphodiesterase type 5 inhibitors (PDE5Is), muscarinic receptor antagonists (MRAs), b3-adrenoceptor agonists, and plant extracts. Of these, the most commonly used drugs in the clinic are a1adrenoceptor antagonists, 5-ARIs, and combination therapy. However, these drugs exert their effects via various mechanisms and are associated with adverse reactions. The purpose of this review is to provide current comprehensive perspectives on the mechanisms of action, efficacy, and adverse reactions associated with the drugs most commonly used for the treatment of BPH.

show abstract

Section: Plant Extractsmentioning

confidence: 99%

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Yan

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Benign prostatic hyperplasia (BPH), a chronic condition in aging men, is characterized by non-malignant enlargement of stromal and epithelial cells in the prostate [1, 2]. Although the etiology of BPH is not fully understood, some factors, such as hormonal disruption, inflammation, and oxidative stress, are clearly associated with the development of BPH [3, 4].…”

Section: Introductionmentioning

confidence: 99%

Effects of inflammatory responses, apoptosis, and STAT3/NF-κB- and Nrf2-mediated oxidative stress on benign prostatic hyperplasia induced by a high-fat diet

Shi

Dong

et al. 2019

Aging

View full text Add to dashboard Cite

This study determined whether or not benign prostatic hyperplasia (BPH) induced by a high-fat diet (HFD) is involved in inflammatory responses, apoptosis, and the signal transducer and activator of transcription (STAT3)/nuclear factor-kappa B (NF-κB)- and nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated oxidative stress pathways. Forty rats were divided into four groups: control; HFD; testosterone; and HFD+testosterone. Hematoxylin and eosin (HE) staining was used to assess histologic changes. An enzyme-linked immunosorbent assay and Western blot analysis were used to detect levels of related proteins. Compared with the control group, the prostate levels of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), malondialdehyde (MDA), transforming growth factor-β1 (TGF-β1), and monocyte chemotactic protein-1 (MCP-1) were significantly increased, while the levels of glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and superoxide dismutase (SOD) were decreased. The TNF-κB, Bcl-2, and caspase-3 levels were increased, while the Bax level was markedly decreased. The cytoplasmic expression of STAT3 and NF-κB was increased, while the nuclear expression of Nrf2 was markedly decreased compared with the control group. In summary, our results demonstrated that a long-term HFD might cause changes in inflammatory responses, apoptosis, and oxidative stress, thus contributing to prostatic hyperplasia. The underlying mechanisms might be related to the STAT3/NF-κB- and Nrf2-mediated oxidative stress pathway.

show abstract

“…These phytoconstituents of Funtumia africana and Abutilon mauritianum, as seen in other plants, have been shown to possess inhibitory effects against 5-alpha reductase, anti-inflammatory and free radical scavenging activities, modulatory effects on prolactininduced prostatic growth and protective effects on bladder and detrusor function (Sharma et al, 2017).…”

Section: Introductionmentioning

confidence: 96%

“…More attention has been channeled towards phytotherapeutics in terms of providing a more effective and safer treatment strategy for patients with BPH, with many plants showing significant anti-BPH effects (Sharma et al, 2017), including aqueous extracts of Metapanax delavayi (Sun et al, 2020) and Yongdamsagan-tang (Park et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Combined ethanol extract of Funtumia africana and Abutilon mauritianium leaves improves the lipid profile and kidney function indices of benign prostatic hyperplasia in rats

Uroko

Chukwu

Egba

et al. 2020

Acta Sci Pol Technol Aliment

View full text Add to dashboard Cite

Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview

Abstract: This article give a brief account of rationale and efficacy of various existing phytotherapeutic agents in the management of benign prostatic hyperplasia, including the herbs which hold the potential promise are also mentioned, although much research is still required.

Cited by 22 publications

References 0 publications

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Effects of inflammatory responses, apoptosis, and STAT3/NF-κB- and Nrf2-mediated oxidative stress on benign prostatic hyperplasia induced by a high-fat diet

Combined ethanol extract of Funtumia africana and Abutilon mauritianium leaves improves the lipid profile and kidney function indices of benign prostatic hyperplasia in rats

Contact Info

Product

Resources

About